Pancreatic Cancer

GemOx more effective than gemcitabine alone in pancreatic cancer study

Published in Cancer Weekly, July 6th, 2004

The final results of a phase III trial comparing the combination of gemcitabine (Gem) and Eloxatin (oxaliplatin for injection) (Ox) to gemcitabine alone were presented at the 40th annual meeting of the American Society of Clinical Oncology (ASCO).

This randomized trial demonstrated that the addition of Eloxatin to gemcitabine, the current standard chemotherapy for pancreatic cancer, achieved significantly better results than gemcitabine alone in terms of response rate, progression-free survival, and clinical benefit response.

The difference did not reach statistical significance in terms of overall survival.

"The results of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry